Cytomx Therapeutics

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with the vision of transforming lives through safer and more effective therapies. The company is developing a new class of investigational antibody therapies based on our Probody® technology platform for the treatment of cancer. CytomX has established strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb. CytomX's clinical-stage pipeline includes potential first-in-class candidates targeting previously undruggable targets, including the CD166-targeting Probody drug conjugate (CX-2009), which is wholly owned by CytomX, and the CD71-targeting Probody drug conjugate (CX-2029) developed in collaboration with AbbVie. CD166 and CD71 are among the cancer targets considered inaccessible by conventional antibody-drug conjugates because they are present in many healthy tissues.